|
COPYRIGHT 2002 The Philadelphia Inquirer
Byline: Linda Loyd
Jul. 13--Wyeth may have thought all the bad news was behind it when the pharmaceutical company changed its name from American Home Products Corp. in March, two months after completing $13.2 billion in settlements of its "fen-phen" diet-drug litigation.
But the Madison, N.J., drugmaker, which employs 4,000 people in the Philadelphia region, got more bad news last week. A national study of the effects of one of its top-selling hormone replacement treatments, Prempro, was halted by the National Institutes of Health.
The 16,000 women in the study got letters telling them to stop taking the combination of estrogen and progestin because of increased risk...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
